RE:RE:RE:RE:RE:RE:Pricing failureIf TH-1902 is shown to work, money to fund further research on it and the many varieties of treatments it will spawn will not be a problem. But we need to hear an affirmative on the proof of concept question first.
As I made abundantly clear, the ONO was a huge setback in my relationship with TH management. I talk to them but far less frequently but am still supportive. Theyare really, really bad at working with the capital marekts but I think they are pretty good otherwise. There is also not as much reason to speak with them now. Either TH-1902 works or it doesn't and that will be determined in the phase 1b. We will hear about it as soon as they have seen an indication fo preliminary efficacy. Not a whole lot else really matters right now. If it works, the company has a very interesting future and will likely get off a decent financing. If it doesn't the stock's future rests on Egrifta and Trogarzo, which are fine but not exciting and whatever offering is done will not be helpful.
canadapiet wrote: I'm wondering......
All those years, you (or your "fund") are invested in this company with a lot of money, because you did your dd and thought it was a good investing!
Over the years, this company did deliver with their products but the earnings didn't follow......!!
Now, they are changing their "core" (hiv) to 2 new possibilities, oncology and Nash.
Nash is on hold and oncology is so premature, so if they want to explore, it will cost a lot, a whole lot of money, that they do not have!!!
Management is allready a bit different, so the company became a rather "new" one.
Do you have the same interactions with management like before?? Why still invested here if company changed in many ways?? Why not more "connected" with management if so long a loyal investor??
Etc..............
Thx in advance
SPCEO1 - Yes, it would have been very nice if the phase 1a went smoother than it apparently did so that so much time was not lost. But drug trials, particularly ones that are utilizing incredily sick people to test on, are going to be more challenging to complete than most drug trials and most drug trials take longer than expected anyway. The next challenge for the phase 1b, as Wino has pointed out, is getting enrollment going at a reasonable rate. That is another matter that often goes slower than anticipated and causes drug trials to take longer than first estimated.